-
1
-
-
84866493384
-
The reluctant surgeon
-
Garden City, New York: Doubleday & Company, Inc
-
Kober J. The reluctant surgeon. A biography of John Hunter. Garden City, New York: Doubleday & Company, Inc.; 1960.
-
(1960)
A Biography Of John Hunter
-
-
Kober, J.1
-
3
-
-
84944482999
-
The transparent chamber of the rabbits ear, giving a complete description of improved technic of construction and introduction, and general account of growth and behavior of living cells and tissues as seen with the microscope
-
Sandison J. The transparent chamber of the rabbits ear, giving a complete description of improved technic of construction and introduction, and general account of growth and behavior of living cells and tissues as seen with the microscope. Am J Anat. 1928;41:447-72.
-
(1928)
Am J Anat
, vol.41
, pp. 447-72
-
-
Sandison, J.1
-
4
-
-
0000912662
-
Vascularization of the Brown-Pearce rabbit epitheioma transplant as seen in the transparent ear chamber
-
Ide A, Baker N, Warren S, et al. Vascularization of the Brown-Pearce rabbit epitheioma transplant as seen in the transparent ear chamber. Am J Roentgenol. 1939;42:891-9.
-
(1939)
Am J Roentgenol
, vol.42
, pp. 891-9
-
-
Ide, A.1
Baker, N.2
Warren, S.3
-
6
-
-
0024384470
-
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
-
DOI 10.1016/0006-291X(89)92678-8
-
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-8. (Pubitemid 19162712)
-
(1989)
Biochemical and Biophysical Research Communications
, vol.161
, Issue.2
, pp. 851-858
-
-
Ferrara, N.1
Henzel, W.J.2
-
7
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-9. (Pubitemid 27441066)
-
(1997)
Cancer Research
, vol.57
, Issue.20
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'Connor, S.J.3
Chisholm, V.4
Meng, Y.G.5
Krummen, L.6
Winkler, M.7
Ferrara, N.8
-
8
-
-
19744368302
-
Cancer of the ovary
-
Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-29.
-
(2004)
N Engl J Med
, vol.351
, pp. 2519-29
-
-
Cannistra, S.A.1
-
9
-
-
63449129599
-
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
-
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234-44.
-
(2009)
Cancer
, vol.115
, pp. 1234-44
-
-
Du Bois, A.1
Reuss, A.2
Pujade-Lauraine, E.3
Harter, P.4
Ray-Coquard, I.5
Pfisterer, J.6
-
10
-
-
77956285631
-
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
-
Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.
-
(2010)
N Engl J Med
, vol.363
, pp. 943-53
-
-
Vergote, I.1
Trope, C.G.2
Amant, F.3
-
11
-
-
0041329867
-
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
-
du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-9.
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 1320-9
-
-
Du Bois, A.1
Luck, H.J.2
Meier, W.3
-
12
-
-
0141688377
-
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
-
DOI 10.1200/JCO.2003.02.153
-
Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-200. (Pubitemid 46606249)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.17
, pp. 3194-3200
-
-
Ozols, R.F.1
Bundy, B.N.2
Greer, B.E.3
Fowler, J.M.4
Clarke-Pearson, D.5
Burger, R.A.6
Mannel, R.S.7
DeGeest, K.8
Hartenbach, E.M.9
Baergen, R.10
Mackey, D.11
-
13
-
-
77950654584
-
TIMP-1 and VEGF-165 serum concentration during first- line therapy of ovarian cancer patients
-
Mahner S, Woelber L, Eulenburg C, et al. TIMP-1 and VEGF-165 serum concentration during first- line therapy of ovarian cancer patients. BMC Cancer. 2010;10:139.
-
(2010)
BMC Cancer
, vol.10
, pp. 139
-
-
Mahner, S.1
Woelber, L.2
Eulenburg, C.3
-
14
-
-
0036793818
-
Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer
-
Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clin Cancer Res. 2002;8:3193-7. (Pubitemid 35155030)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.10
, pp. 3193-3197
-
-
Cooper, B.C.1
Ritchie, J.M.2
Broghammer, C.L.W.3
Coffin, J.4
Sorosky, J.I.5
Buller, R.E.6
Hendrix, M.J.C.7
Sood, A.K.8
-
15
-
-
0033061333
-
Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome
-
Gadducci A, Ferdeghini M, Fanucchi A, et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome. Anticancer Res. 1999;19:1401-5. (Pubitemid 29257466)
-
(1999)
Anticancer Research
, vol.19
, Issue.2 B
, pp. 1401-1405
-
-
Gadducci, A.1
Ferdeghini, M.2
Fanucchi, A.3
Annicchiarico, C.4
Ciampi, B.5
Prontera, C.6
Genazzani, A.R.7
-
16
-
-
59449084872
-
Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model
-
Mabuchi S, Terai Y, Morishige K, et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res. 2008;14:7781-9.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7781-9
-
-
Mabuchi, S.1
Terai, Y.2
Morishige, K.3
-
17
-
-
79957457473
-
Die Qualität der Therapie des Ovarialkarzinoms in Deutschland
-
du Bois A, Rochon J, Lamparter C, et al. Die Qualität der Therapie des Ovarialkarzinoms in Deutschland. Frauenarzt. 2009;50:742-51.
-
(2009)
Frauenarzt
, vol.50
, pp. 742-51
-
-
Du Bois, A.1
Rochon, J.2
Lamparter, C.3
-
18
-
-
73949092398
-
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors
-
Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28:154-9.
-
(2010)
J Clin Oncol
, vol.28
, pp. 154-9
-
-
Penson, R.T.1
Dizon, D.S.2
Cannistra, S.A.3
-
19
-
-
79960679604
-
A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma
-
Brown JV III, Micha JP, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH. A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer. 2010;20:1132-36.
-
(2010)
Int J Gynecol Cancer
, vol.20
, pp. 1132-36
-
-
Brown III, J.V.1
Micha, J.P.2
Rettenmaier, M.A.3
Abaid, L.N.4
Lopez, K.L.5
Goldstein, B.H.6
-
20
-
-
34447298651
-
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
-
DOI 10.1111/j.1525-1438.2007.00886.x
-
Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17:771-6. (Pubitemid 47063333)
-
(2007)
International Journal of Gynecological Cancer
, vol.17
, Issue.4
, pp. 771-776
-
-
Micha, J.P.1
Goldstein, B.H.2
Rettenmaier, M.A.3
Genesen, M.4
Graham, C.5
Bader, K.6
Lopez, K.L.7
Nickle, M.8
Brown III, J.V.9
-
21
-
-
83355169742
-
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
-
Konner JA, Grabon DM, Gerst SR, et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol. 2011;29:4662-8.
-
(2011)
J Clin Oncol
, vol.29
, pp. 4662-8
-
-
Konner, J.A.1
Grabon, D.M.2
Gerst, S.R.3
-
22
-
-
84855425106
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer
-
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-83.
-
(2011)
N Engl J Med
, vol.365
, pp. 2473-83
-
-
Burger, R.A.1
Brady, M.F.2
Bookman, M.A.3
-
23
-
-
84855466019
-
A phase 3 trial of bevacizumab in ovarian cancer
-
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-96.
-
(2011)
N Engl J Med
, vol.365
, pp. 2484-96
-
-
Perren, T.J.1
Swart, A.M.2
Pfisterer, J.3
-
24
-
-
84874190315
-
Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST)
-
AGO Study Group Available at: Accessed June 1 2012
-
AGO Study Group. Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST). ClinicalTrials no. NCT01462890. Available at: http://clinicaltrials.gov/ct2/show/NCT01462890. Accessed June 1 2012.
-
Clinical Trials no NCT01462890
-
-
-
28
-
-
80051913984
-
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference
-
Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21:750-5.
-
(2011)
Int J Gynecol Cancer
, vol.21
, pp. 750-5
-
-
Stuart, G.C.1
Kitchener, H.2
Bacon, M.3
-
29
-
-
67549084366
-
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
-
Meier W, du Bois A, Reuss A, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2009;114:199-205.
-
(2009)
Gynecol Oncol
, vol.114
, pp. 199-205
-
-
Meier, W.1
Du Bois, A.2
Reuss, A.3
-
30
-
-
34447570846
-
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
-
DOI 10.1200/JCO.2006.09.6735
-
Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811-18. (Pubitemid 47123191)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.19
, pp. 2811-2818
-
-
Mutch, D.G.1
Orlando, M.2
Goss, T.3
Teneriello, M.G.4
Gordon, A.N.5
McMeekin, S.D.6
Wang, Y.7
Scribner Jr., D.R.8
Marciniack, M.9
Naumann, R.W.10
Secord, A.A.11
-
31
-
-
39749113438
-
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
-
DOI 10.1200/JCO.2007.13.6606
-
Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890-6. (Pubitemid 351398081)
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.6
, pp. 890-896
-
-
Ferrandina, G.1
Ludovisi, M.2
Lorusso, D.3
Pignata, S.4
Breda, E.5
Savarese, A.6
Del Medico, P.7
Scaltriti, L.8
Katsaros, D.9
Priolo, D.10
Scambia, G.11
-
32
-
-
0030900145
-
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
-
ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-93. (Pubitemid 27251118)
-
(1997)
Journal of Clinical Oncology
, vol.15
, Issue.6
, pp. 2183-2193
-
-
Huinink, W.T.B.1
Gore, M.2
Carmichael, J.3
Gordon, A.4
Malfetano, J.5
Hudson, I.6
Broom, C.7
Scarabelli, C.8
Davidson, N.9
Spanczynski, M.10
Bolis, G.11
Malmstrom, H.12
Coleman, R.13
Fields, S.C.14
Heron, J.-F.15
-
33
-
-
0037862963
-
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial
-
Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-106.
-
(2003)
Lancet
, vol.361
, pp. 2099-106
-
-
Parmar, M.K.1
Ledermann, J.A.2
Colombo, N.3
-
34
-
-
33750588670
-
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
-
DOI 10.1200/JCO.2006.06.0913
-
Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-707. (Pubitemid 46630933)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.29
, pp. 4699-4707
-
-
Pfisterer, J.1
Plante, M.2
Vergote, I.3
Du Bois, A.4
Hirte, H.5
Lacave, A.J.6
Wagner, U.7
Stahle, A.8
Stuart, G.9
Kimmig, R.10
Olbricht, S.11
Le, T.12
Emerich, J.13
Kuhn, W.14
Bentley, J.15
Jackisch, C.16
Luck, H.-J.17
Rochon, J.18
Zimmermann, A.H.19
Eisenhauer, E.20
more..
-
35
-
-
77954726606
-
Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
-
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-9.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3323-9
-
-
Pujade-Lauraine, E.1
Wagner, U.2
Aavall-Lundqvist, E.3
-
37
-
-
36849056497
-
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
-
DOI 10.1200/JCO.2007.12.0782
-
Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-6. (Pubitemid 350232248)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.33
, pp. 5180-5186
-
-
Cannistra, S.A.1
Matulonis, U.A.2
Penson, R.T.3
Hambleton, J.4
Dupont, J.5
Mackey, H.6
Douglas, J.7
Burger, R.A.8
Armstrong, D.9
Wenham, R.10
McGuire, W.11
-
38
-
-
37849035249
-
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia
-
Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26:76-82.
-
(2008)
J Clin Oncol
, vol.26
, pp. 76-82
-
-
Garcia, A.A.1
Hirte, H.2
Fleming, G.3
-
39
-
-
36849019301
-
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study
-
DOI 10.1200/JCO.2007.11.5345
-
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165-71. (Pubitemid 350237599)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.33
, pp. 5165-5171
-
-
Burger, R.A.1
Sill, M.W.2
Monk, B.J.3
Greer, B.E.4
Sorosky, J.I.5
-
40
-
-
35348904080
-
Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
-
DOI 10.1016/j.ygyno.2007.07.017, PII S0090825807004635
-
Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2007;107:326-30. (Pubitemid 47575735)
-
(2007)
Gynecologic Oncology
, vol.107
, Issue.2
, pp. 326-330
-
-
Chura, J.C.1
Van Iseghem, K.2
Downs Jr., L.S.3
Carson, L.F.4
Judson, P.L.5
-
41
-
-
45549099056
-
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia
-
Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008;110:49-55.
-
(2008)
Gynecol Oncol
, vol.110
, pp. 49-55
-
-
Nimeiri, H.S.1
Oza, A.M.2
Morgan, R.J.3
-
42
-
-
67651055473
-
Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer
-
Smerdel MP, Waldstrom M, Brandslund I, Steffensen KD, Andersen RF, Jakobsen A. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:578-84.
-
(2009)
Int J Gynecol Cancer
, vol.19
, pp. 578-84
-
-
Smerdel, M.P.1
Waldstrom, M.2
Brandslund, I.3
Steffensen, K.D.4
Andersen, R.F.5
Jakobsen, A.6
-
43
-
-
79960473821
-
Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
-
Kudoh K, Takano M, Kouta H, et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol. 2011;122:233-7.
-
(2011)
Gynecol Oncol
, vol.122
, pp. 233-7
-
-
Kudoh, K.1
Takano, M.2
Kouta, H.3
-
44
-
-
80053935580
-
Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results
-
Abstract 5548
-
Muggia FM, Boyd L, Liebes L, et al. Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results. J Clin Oncol 2009;27 (Suppl.):15s (Abstract 5548).
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.15
-
-
Muggia, F.M.1
Boyd, L.2
Liebes, L.3
-
45
-
-
80051549914
-
Combined weekly topotecan and biweekly bevacizumab in women with platinumresistant ovarian, peritoneal, or fallopian tube cancer: Results of a phase 2 study
-
McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinumresistant ovarian, peritoneal, or fallopian tube cancer: Results of a phase 2 study. Cancer. 2011;117:3731-40.
-
(2011)
Cancer
, vol.117
, pp. 3731-40
-
-
McGonigle, K.F.1
Muntz, H.G.2
Vuky, J.3
-
46
-
-
84864396971
-
A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinumsensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer
-
Del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinumsensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2012;126:369-74.
-
(2012)
Gynecol Oncol
, vol.126
, pp. 369-74
-
-
Del Carmen, M.G.1
Micha, J.2
Small, L.3
Street, D.G.4
Londhe, A.5
McGowan, T.6
-
47
-
-
80053229517
-
OCEANS: A randomized, double-blinded, placebocontrolled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
-
Abstract LBA5007
-
Aghajanian C, Finkler N, Rutherford T, et al. OCEANS: A randomized, double-blinded, placebocontrolled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol. 2011;29 (Suppl.). Abstract LBA5007.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Aghajanian, C.1
Finkler, N.2
Rutherford, T.3
-
48
-
-
84866493383
-
AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
-
Abstract LBA5002
-
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl.). Abstract LBA5002.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Pujade-Lauraine, E.1
Hilpert, F.2
Weber, B.3
Reuss, A.4
Poveda, A.5
Kristensen, G.6
-
49
-
-
79953863317
-
Big costs for little gain in ovarian cancer
-
Hensley ML. Big costs for little gain in ovarian cancer. J Clin Oncol. 2011;29:1230-2.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 1230-2
-
-
Hensley, M.L.1
-
50
-
-
79953893326
-
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis
-
Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol. 2011;29:1247-51.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 1247-51
-
-
Cohn, D.E.1
Kim, K.H.2
Resnick, K.E.3
O'Malley, D.M.4
Straughn Jr., J.M.5
|